Saltar al contenido
MilliporeSigma

N1165

Sigma-Aldrich

Pimonidazole

≥98% (HPLC)

Sinónimos:

NSC 380540, PD 126675;, Ro 03-8799;, alpha-((2-Nitroimidazol-1-yl)methyl)-1-piperidineethanol;, alpha-[(2-Nitro-1H-imidazol-1-yl)methyl]-1-piperidineethanol

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C11H18N4O3
Número de CAS:
Peso molecular:
254.29
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

assay

≥98% (HPLC)

form

powder

color

yellow

solubility

DMSO: >20 mg/mL

storage temp.

2-8°C

SMILES string

OC(CN1CCCCC1)Cn2ccnc2[N+]([O-])=O

InChI

1S/C11H18N4O3/c16-10(8-13-5-2-1-3-6-13)9-14-7-4-12-11(14)15(17)18/h4,7,10,16H,1-3,5-6,8-9H2

InChI key

WVWOOAYQYLJEFD-UHFFFAOYSA-N

Biochem/physiol Actions

Pimonidazole is an effective and nontoxic exogenous 2-nitroimidazole hypoxia marker. Pimonidazole forms adducts with thiol groups in proteins, peptides and amino acids.
Pimonidazole possesses a nitro group at position 2 and an imidazole ring. Pimonidazole undergoes reduction and is activated in hypoxic cells.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Hypoxia Studies with Pimonidazole in vivo
Aguilera KY and Brekken RA
Bio-protocol, 4(19) (2014)
Glyn Chidlow et al.
Frontiers in neuroscience, 11, 478-478 (2017-09-09)
The vascular hypothesis of glaucoma proposes that retinal ganglion cell axons traversing the optic nerve head (ONH) undergo oxygen and nutrient insufficiency as a result of compromised local blood flow, ultimately leading to their degeneration. To date, evidence for the
Lena-Christin Conradi et al.
Angiogenesis, 20(4), 599-613 (2017-09-07)
Blockade of the glycolytic activator PFKFB3 in cancer cells (using a maximum tolerable dose of 70 mg/kg of the PFKFB3 blocker 3PO) inhibits tumor growth in preclinical models and is currently being tested as a novel anticancer treatment in phase I
Hanneke Stegeman et al.
Head & neck, 36(9), 1288-1295 (2014-03-29)
Hypoxia, metabolism, and growth factor signaling are important prognostic features in most solid tumors. The purpose of this study was to determine whether head and neck squamous cell carcinoma (HNSCC) xenografts show similar biological and molecular characteristics as the primary
Esther A Kleibeuker et al.
Oncotarget, 7(47), 76613-76627 (2016-10-27)
The extent of tumor oxygenation is an important factor contributing to the efficacy of radiation therapy (RTx). Interestingly, several preclinical studies have shown benefit of combining RTx with drugs that inhibit tumor blood vessel growth, i.e. angiostatic therapy. Recent findings

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico